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ABSTRACT 
Background 
A number of human inflammatory diseases and tumors have been shown to cause alterations 
in the glycosylation pattern of plasma proteins in a specific manner. These highly variable and 
versatile post-translational modifications fine-tune protein functions by influencing sorting, 
folding, enzyme activity and subcellular localization. However, relatively little is known 
about regulatory factors of this procedure and about the accurate causative connection 
between glycosylation and disease. 
Objective 
The aim of the present study was to investigate whether certain single nucleotide 
polymorphisms (SNPs) in genes encoding glycosyltransferases and glycosidases could be 
associated with elevated risk for chronic obstructive pulmonary disease (COPD) and lung 
adenocarcinoma. 
Methods 
A total of 32 SNPs localized in genes related to N-glycosylation were selected for the 
association analysis. Polymorphisms with putative biological functions (missense or 
regulatory variants) were recruited. SNPs were genotyped by a TaqMan OpenArray platform. 
A single base extension based method in combination with capillary gel electrophoresis was 
used for verification. 
Results 
The TaqMan OpenArray approach provided accurate and reliable genotype data (global call 
rate: 94.9%, accuracy: 99.6%). No significant discrepancy was detected between the obtained 
and expected genotype frequency values (Hardy–Weinberg equilibrium) in the healthy control 
sample group in case of any SNP confirming reliable sampling and genotyping. Allele 
frequencies of the rs3944508 polymorphism localized in the 3’ UTR of the MGAT5 gene 
significantly differed in the sample groups compared. 
Conclusion 
Our results suggest that the rs34944508 SNP might modulate the risk for lung cancer by 
influencing the expression of MGAT5. This enzyme catalyzes the addition of N-
acetylglucosamine (GlcNAc) in beta 1-6 linkage to the alpha-linked mannose of biantennary 
N-linked oligosaccharides, thus, increases branching that characteristic for invasive 
malignancies. 
 
3 
INTRODUCTION 
Protein glycosylation has long been known as one of the most common, highly variable and 
versatile post-translational modifications that fine-tunes protein functions by modulating 
sorting, folding, enzyme activity and subcellular localization [1, 2]. The astounding diversity 
of protein-attached glycans is the result of the concerted action of glycosyltransferases and 
glycosidases, which function is template-independent. To date, however, relatively little is 
known about the regulatory factors, which coordinate the tissue-specific establishment, 
maintenance and dynamic modulation of protein glycosylation patterns across the body [3, 4]. 
The advent of high-throughput analytical methods such as reversed phase liquid 
chromatography and capillary electrophoresis, especially when connected to mass 
spectroscopy have shed light on marked individual variability of the glycoproteome [4-6]. It 
also turned out that cells respond to various environmental effects by dynamically altering 
their global glycosylation patterns, and recent advances in the burgeoning field of 
glycoproteomics have contributed a great deal to our better understanding of disease-
associated alterations of the glycome [7, 8]. 
 
A number of human inflammatory diseases and tumors seems to influence the glycosylation 
patterns of plasma proteins in a specific manner, making them potential candidates in the 
quest to find reliable and easily accessible biomarkers [9, 10]. N-glycan profiling of plasma 
proteins unveiled characteristic alterations both in systemic [11, 12] and organ-specific 
inflammation [13], and the diagnosis of pancreatic [14, 15], breast [16, 17] and ovarian [18, 
19] cancer might be corroborated by early N-glycosylation analysis. Moreover, serum N-
glycans might help to discriminate between benign and malignant tumors [20], predict the 
prognosis in terms of recurrence and metastasis [21] and the propagation of chronic viral 
hepatitis to cirrhosis and eventually hepatocellular carcinoma [22]. Another relevant example 
for the inflammation-to-malignancy transition is chronic obstructive pulmonary disease 
(COPD), a chronic airway inflammation, which is a common risk factor for lung cancer with 
overlapping genetic background [23]. As of today, several serum glycan biomarkers 
predictive for lung cancer have been described [24-26], and we recently reported that 
differences in fucosylation levels and positional isomer types of plasma haptoglobin can help 
to distinguish between COPD and pulmonary cancer [27]. 
Cancer-specific disturbances in N-glycan profiles might emerge due to genomic sequence 
variants occurring either in the coding or regulatory regions of key glycosylation enzymes 
[28]. Length or point polymorphisms in promoters or in 3’ untranslated regions can result in 
subtle changes in their expression levels by modulating transcription factor or miRNA 
binding affinities [29, 30], respectively, while missense mutations often lead to altered 
activities or substrate specificities. Theoretically, further disturbances in the glycoproteome 
might arise due to variations in consensus glycosylation sequences in target proteins [31] or 
altered synthesis or cellular uptake of precursor carbohydrates. However, it is still unclear 
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whether altered glycosylation patterns play an indispensable role in the acquisition of cancer-
specific hallmarks, or they occur as mere consequences of the malignant transformation [32]. 
 
The aim of the present study was to clarify whether certain single nucleotide polymorphisms 
(SNPs) in genes encoding glycosyltransferases and glycosidases could be associated with 
elevated risk for chronic obstructive pulmonary disease (COPD) and lung adenocarcinoma. 
To this end, cohorts of COPD, lung cancer and co-morbid patients as well as healthy controls 
were genotyped using two different methodologies, a high-throughput, TaqMan probe based 
OpenArray platform approach [33] and primer extension combined with capillary 
electrophoresis [34]. 
 
 
MATERIALS AND METHODS 
Participants, DNA-sampling and -purification 
Non-related Hungarian (Caucasian) male and female subjects (age: 40–85 years) participated 
in our study. People of different ethnic origin were excluded from the analyses to avoid 
population stratification. Participants signed written informed consent and the study protocol 
was approved by the Scientific and Research Ethics Committee of the Medical Research 
Council (ETT TUKEB ad.328/KO/2005, ad.323-86/2005-1018EKU). 
Participants suffering from COPD or bronchial cancer were selected from patients treated in 
“Borsod-Abaúj-Zemplén” County Central Hospital (Miskolc, Hungary). Patients with other 
respiratory disease, such as asthma, sarcoidosis, tuberculosis, lung fibrosis, cystic fibrosis, as 
well as any tumor or oncological treatment in the past 5 years were excluded from the study. 
COPD was diagnosed according to the protocol of GOLD 2016 (Global initiative of 
Obstructive Lung Disease) based on the result of spirometry examination. Diagnosis of 
COPD was stated if the FEV1 / FVC ratio (Tiffeneau-Pinelli index – proportion of forced 
expiratory volume in the first second to the forced vital capacity) was less than 0.7. Current 
spirometry data were taken into consideration in case of patients with stable condition, 
whereas earlier data were used for subjects with acute exacerbating COPD. Subjects of the 
lung cancer group were selected from patients with recent diagnosis confirmed by histology 
or cytology, who has not received any antitumor therapy yet. Members of the control group 
were volunteers with similar smoking habit, however, without any pulmonary disease in their 
medical history. Based on these aspects, subjects were categorized into the following four 
groups: (1) healthy control (N = 294), (2) COPD (N = 308), (3) lung cancer (N = 312) and (4) 
comorbid COPD and lung cancer (N = 179). The four patient groups were matched according 
to age (51–78 years old, average: 64) and sex (male: 52%, female: 48%). 
The study was approved by the Scientific and Research Ethics Committee of the Medical 
Research Council, ETT TUKEB ad.328/KO/2005, ad.323-86/2005-1018EKU, Hungary. No 
animals were used in this study, reported experiments on humans were followed in 
accordance with the ethical standards of the committee responsible for human 
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experimentation (Scientific and Research Ethics Committee of the Medical Research Council 
– “ETT TUKEB”), and with the Helsinki Declaration of 1975, as revised in 2008 
(http://www.wma.net/en/20activities/10ethics/10helsinki/). Written consent was obtained 
from the individuals. 
 
DNA-samples were collected by rubbing epithelial cells from the inner surface of the cheek or 
gum using cotton swabs. DNA isolation was initiated by cell lysis in a 0.2 mg/mL Proteinase 
K buffer solution (56 °C, 3 hours or overnight). Proteins were precipitated by the addition of 
saturated NaCl. After centrifugation (13,000 rpm, 20 min, 4 °C) DNA was precipitated from 
the supernatant by isopropanol, then pellet was washed by 70% ethanol. Finally, DNA was 
resolved in 0.5× TE buffer solution (5 mM Tris-HCl, pH 8.0; 0.5 mM EDTA). Concentration 
of the DNA-samples was measured by NanoDrop1000 spectrophotometer (Thermo Scientific, 
Waltham, MA, USA). 
 
Multiplex SNP Analysis by Single Base Primer Extension and Denaturing CE 
The first step of the genotype analyses was the amplification of the DNA-sequences flanking 
the SNPs of interest. PCR-primers were designed by NCBI Primer-Blast 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/). Data about each PCR primer are 
summarized in Table 1. The Qiagen HotStarTaq DNA-polymerase kit including the DNA-
polymerase, a reaction buffer and a “Q-solution” was employed for amplification. Reactions 
were performed in a total volume of 12 µL. The flanking regions of the SNPs were amplified 
in multiplex PCR. Reaction mixtures contained 0.2 mM of each deoxyribonucleoside-
triphosphate, 0.1 µM of the appropriate primers, 0.3 U of HotStarTaq DNA-polymerase, 1× 
buffer, 1× Q-solution and approximately 5 ng of genomic DNA. The first step of the 
thermocycle was the initial denaturation at 95 °C for 15 min to activate the HotStarTaq DNA-
polymerase. It was followed by 35 cycles of denaturation (94 °C – 1 min), annealing (67 °C – 
30 sec) and extension (72 °C – 1 min). PCR was completed by a final extension at 72 °C for 
10 min and the samples were then kept at 8 °C until downstream analyses. Aliquots of the 
PCR products were analyzed by sub-marine agarose gel-electrophoresis to verify the optimal 
formation of each product in the multiplex PCR. Products were then treated by Exonuclease I 
and Shrimp Alkaline Phosphatase (New England Biolabs, Ipswich, MA) to eliminate excess 
primers and dNTPs according to manufacturer’s protocols. 
The SNPStart solution (Beckman Coulter, Brea, CA) contained the components (fluorescently 
labeled acyclo-terminators, DNA-polymerase and buffer) of the SBE reaction in a pre-mixed 
form. Reactions were carried out in 10 µL final volume, which contained 4 µL master mix, 
100 fmol product of the 1st PCR and 15 pmol SBE primer. PCR consisted of 30 cycles of 90 
°C denaturation for 10 sec, 55 °C annealing for 20 sec and 72 °C extension for 1 minute. Dye 
terminators not incorporated into the products were eliminated by Shrimp Alkaline 
Phosphatase (New England Biolabs) digestion according to the manufacturer’s protocols. 0.5 
µL of SBE reaction product was then added to 39 µL of Sample Loading Solution and 0.5 µL 
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of Size Standard 80 (Beckman Coulter). Samples were then covered with one drop of mineral 
oil. Multicapillary gel electrophoresis analysis was carried out in a GenomeLab™ GeXP 
Genetic Analysis System (SCIEX, Brea, CA) using the following parameters: capillary 
temperature: 50 °C, denaturation: 90 °C for 60 sec, sample injection 2.0 kV for 30 sec, 
separation: 6.0 kV for 1 min. SNP ver2 dye mobility correction was employed for data 
analysis. 
 
SNP Analysis by TaqMan® OpenArray® system 
The TaqMan® OpenArray® system was used for the genotype determination of a set of SNPs 
listed in Table 2. Genomic DNA samples were diluted to adjust their concentration in the 
range of 20–50 ng/µL. 2.5 µl of the samples were mixed with 2.5 µL TaqMan™ 
OpenArray™ Genotyping PCR Master Mix containing the AmpliTaq Gold® DNA-
polymerase and the deoxyribonucleoside-triphosphates (dATP, dCTP, dGTP and dTTP) 
buffer (ThermoFisher, Waltham MA) in a 384-well-plate. This plate is used by the 
OpenArray™ AccuFill™ System (ThermoFisher, Waltham MA), which loads the reaction 
mixture on the TaqMan™ OpenArray™ Genotyping Plates (ThermoFisher). These plates 
were divided into 48 subarrays, each consisting of 64 through-holes allowing to perform 3072 
genotype analyses (32 SNPs of 96 samples in our setup) on one single plate. Primers and 
sequence specific TaqMan probes were imposed on the edge of the through-holes and 
dissolved in the reaction mixtures after loading with DNA samples. PCRs were carried out in 
33 nl reaction volume, the thermocycler was operated according to the manufacturer’s 
OpenArray™ Genotyping protocol. Amplification, data collection during PCR as well as 
allelic discrimination protocol clustering the samples into 3 groups according to their 
genotypes were carried out by the QuantStudio™ 12K Flex Real-Time PCR platform. 
Genotype analysis was performed by the TaqMan Genotyper Software and by the cloud 
service (ThermoFisher) called “Connect”. The data supporting the findings of the article are 
available in the ThermoFisher Connect at https://www.thermofisher.com/hu/en/home/digital-
science.html, reference number 2018_CT. 
 
Statistical Analysis 
Reliability of the applied genotyping protocols was verified by testing the Hardy–Weinberg 
equilibrium in case of each locus. SPSS v17.0 was applied to perform 2-test in case–control 
setup to assess genotype–phenotype association. The Bonferroni correction and the False 
Discovery Rate (Benjamini–Hochberg procedure) were used to rule out false positive findings 
caused by multiplex testing. 
 
 
RESULTS AND DISCUSSION 
Two substantially different techniques (Table 3) were used for the genotype analysis of SNPs 
in genes (Table 2) coding for proteins potentially involved in the synthesis of N-glycans in 
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Golgi. The TaqMan® OpenArray® method used in this work was based on the simultaneous 
application of two probes that were labeled with two different fluorescent dyes (VIC and 
FAM) at their 5’ end, and could anneal to the two alleles of the given locus, respectively. This 
allowed genotype determination of one single SNP in each reaction (multiplex analyses 
cannot be performed). The procedure on the other hand consisted of one single step, which in 
combination with the miniaturized, low density “Open Array” format offered extraordinary 
high throughput. The great majority of the genotyping procedures were carried out by this 
technique. 
 
The other approach – also known as “minisequencing” – employed the chain terminating 
acyclo (9-(2-hydroxyethoxy)methyl-) nucleotides labeled with different fluorophores. 
Genotype determination was based on the application of a primer annealing to the nucleotide 
nearby the SNP site with its 3’ end in the single base extension (SBE) reaction. This primer 
was elongated by one single acyclo nucleotide, thus the color of the product allowed 
unambiguous determination of the alleles present in the polymorphic locus. Detection of the 
generated products was carried out by capillary gel electrophoresis (CGE), offering fragment 
size determination as well. This allowed the completion of multiplex assays, as the 
application of SBE primers with different lengths resulted in reaction products that could be 
separated by CGE. The whole analysis consisted of three major steps: 1) first the flanking 
region of the investigated SNPs was amplified. This reaction can also be carried out in a 
multiplex format, or – in case of loci in close proximity with each other – several SNPs can be 
included in one PCR amplicon; 2) The product of this PCR served as a template for the SBE 
reaction, which 3) was followed by CGE analysis. This approach offered excellent reliability, 
however, – despite of the potential of carrying out multiplex measurements – the three 
consecutive steps were time-consuming and labor-intensive, reducing the throughput of the 
workflow. Thus, this technique was used for validation of the real-time PCR based approach 
for a subset of samples and polymorphisms. 
 
Figure 1 shows the results of the representative genotype analyses obtained by the two 
methods. As one can observe, samples with different genotypes form clusters in case in the 
TaqMan assay (Figure 1A). High signal of only one of the two dyes can be observed in case 
of homozygotes (blue and red dots). Heterozygotes are localized in the middle of the graph 
(green dots). No amplification occured in the non-template control (NTC) samples, 
consequently they can be found close to the origin of the graph. The unambiguous 
representation of the three genotypes can be seen in Figure 1B in a single SNP analysis by 
primer extension in combination with high throughput, multiplex CGE. Please note, that this 
CGE-based method possesses outstanding specificity, as absolutely no aspecific signal can be 
observed in case of homozygote samples. 
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A total of 32 SNPs (Table 2) localized in the MGAT5, ST3GAL1, ST6GAL1, FUT2 and 
FUT3 N-glycosylation related genes were selected for the case–control analysis. 
Polymorphisms with putative biological functions were recruited, i.e., missense variants and 
loci in the 5’ UTR, 1st intron or 3’ UTR were involved in our study. In case of the loci 
localized in the 5’ UTR or in the 1st intron an alteration in the efficiency in transcription factor 
binding was suggested by in silico prediction, whereas 3’ UTR SNPs may often modulate the 
mRNA–microRNA interaction, which can lead to the alteration of translation activity. A 
subset of 96 samples were analyzed for the rs2922471 C/T, rs4736675 A/G and rs1042757 
C/G SNPs (Table 1) with both methods resulting in as high as 99.6% concordant results. The 
one single discrepancy was also resolved after verification of the results of the two assays by 
reconsidering the automatically called genotype by the TaqMan® OpenArray® system. Two 
polymorphisms (rs2230908, rs1468906) were excluded from the downstream genotype–
phenotype association study because of ambiguous genotyping data. Samples formed five 
distinct clusters instead of the 3 genotype categories in case of the rs2230908, which might be 
caused by either a copy number variation or another adjacent SNP in the region of the 
investigated locus. In case of the rs1468906 polymorphism the efficiency of the amplification 
was very poor in approximately half of the samples. It was apparently caused by a similar 
issue, i.e., an unknown polymorphism might have inhibited adequate binding of the primers 
or the probes, resulting in the lack of the PCR-product. 
The Hardy–Weinberg equilibrium was used to evaluate the reliability of the genotype analysis 
workflow in case of each SNP. The 2-test did not show any significant discrepancy between 
the obtained and expected genotype frequency values in the healthy control sample group 
confirming reliable sampling and genotyping. 
 
Results of the case–control study are summarized in Table 4. Analysis was carried out in an 
allele-wise manner, i.e., the distribution of the allele-frequency values was compared in the 
four patient groups (controls, patients with COPD, lung cancer and comorbid cases). 
Application of the allele-wise approach helped to avoid false positive findings caused by 
relatively rare genotype categories or by heterozygotes. Significant difference (nominal p < 
0.05) was detected in case of the rs34944508 SNP in the MGAT5 gene and the rs35166820 
polymorphism in ST6GAL1. The latter locus did not reach the level of statistical significance 
after carrying out corrections for multiple testing. It is notable on the other hand that the 
difference in the distribution of the allele frequencies among the four groups remained 
statistically significant in case of the rs34944508 locus using either the FDR (Benjamini–
Hochberg false discovery rate) or the more stringent Bonferroni-correction. Results are 
visualized in Figure 2 showing an outstanding, more than 2× difference in the minor allele 
frequencies of the healthy controls (8.7%) and the patients with lung cancer (3.3%), whereas 
the two other subject groups (COPD: 4.5% and comorbid: 4.1%) possessed intermediate 
values. 
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The 3’ untranslated regions (3’ UTRs) of genes often contain cognate binding sites for 
microRNA. miRNA binding may cause downregulation of translation and/or mRNA 
degradation. Therefore, we raised the question whether the rs34944508 in the 3’ UTR of the 
N-acetylglucosaminyltransferase V (MGAT5) gene might affected the miRNA binding sites. 
Searching in the PolymiRTS database, it turned out that the minor T allele of the SNP creates 
and the common C variant abrogates a binding site for the hsa-miR-3200-3p miRNA. The 
expression of this miRNA has been shown to be controlled by NF-κB in HeLa cells [35], and 
its plasma levels were found to be reduced in Alzheimer disease, making it a potential 
miRNA-biomarker of neurodegeneration [36]. The latter result has been recapitulated in intact 
red blood cells too [37]. 
 
As the C allele was found to be enriched in the lung cancer population, it seemed tempting to 
assume that elevated levels of MGAT5 might be involved in the pathogenesis of pulmonary 
cancer. Our hypothesis is underpinned by the following results. First, the miR-3200-3p has 
been shown to be expressed in lung tissue according to miRGator 3.0, so its potential 
regulatory role in lung cancer is apparently biologically relevant. Second, it was earlier 
reported [38] that siRNA-mediated knockdown of MGAT5 inhibited the growth of lung 
cancer cells both in vitro and in vivo. MGAT5 is a typical cancer-associated 
glycosyltransferase that transfers N-acetylglucosamine residues on mannoses via a β1-6 
linkage [39]. Elevated levels of β1-6 branched glycans are characteristic hallmarks of various 
tumors [40, 41], and overexpression of MGAT5 is frequently seen in cancer [42, 43]. As far 
as the molecular mechanism is concerned, Chiang et al. [44] found that MGAT5 catalyzed the 
N-glycosylation of CEACAM6 (carcinembryonic antigen-related cell adhesion molecule 6), a 
cell surface marker and interacting partner of epidermal growth factor receptor (EGFR). 
Glycosylation of CEACAM6 by MGAT5 is indispensable for EGFR clustering and activation 
as key signaling events leading to invasion and metastasis of oral squamous cell carcinoma.  
 
CONCLUSIONS 
Considering the above, we have identified one significantly associated SNP with lung cancer. 
Further investigations are needed on larger populations to boost the statistical power of this 
potentially novel glycobiomarker in cancer diagnostics. Our results suggest that the 
rs34944508 SNP might modulate the risk for lung cancer by influencing the expression of 
MGAT5, a typical cancer-associated glycosyltransferase. Nevertheless, further functional 
studies (such as luciferase assay) are required to test whether hsa-miR-3200-3p miRNA can 
indeed down-regulate MGAT5 expression levels in a sequence-specific manner. 
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TABLES 
Table 1. Primers used in the single base extension method in combination with capillary 
gel electrophoresis. The two primers designated with “PCR:” were used in the first step to 
amplify the flanking region of the investigated SNP, whereas the primer labeled with “SBE:” 
was applied in the single base extension reaction. 
SNP Primers (uppers: amplification, lower: SBE reaction) Tm (°C) Product 
rs2922471 PCR: 5’ TGGGGCTTTCAGAAAAGGCCTTGCCCA 3’ 62.8 548 bp 
C/T PCR: 5’ GGAGCCCCAGGTCATCCAGCTGTTGC 3’ 65.8 
 SBE: 5’ GTTTTTCAGCTACATTAATATATTGT 
GAGACCACTGTCTTA 3’ 
61.5 42 nt 
rs4736675 PCR: 5’ GTGGCCTTCTCACACCCTCCCGTG 3’ 64.2 
268 bp 
A/G PCR: 5’ CCCTGCCACTGCCTGCCCAGAAC 3’ 64.2 
 SBE: 5’ CCAGGGATGAGTTCCAGTTGGTTTAA 
GCCA 3’ 
63.0 30 nt 
rs1042757 PCR: 5’ AGGAGGTGGCATTCCGACAGCAGG 3’ 62.5 
573 bp 
C/G PCR: 5’ GAGCCAGTGGGTAAGGACTGGGG 3’ 62.4 
 SBE: 5’ TCTGGTGAGATGTTTCATATTTGTGA 
CAGTTAATTTAAAAATTATGA 3’ 
61.1 48 nt 
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Table 2. Single nucleotide polymorphisms investigated by TaqMan™ OpenArray™ in 
the case–control association study. The major allele stands at the first position in the 
“Alleles” column. Chromosomal localization is given according to genome build GRCh38. 
Statistical p value of the 2-analysis of the Hardy–Weinberg equilibrium is shown. MAF: 
Minor allele frequency in the whole sample. 
  dbSNP Alleles Chr. Position Gene 
Call 
rate 
Hardy–
Weinberg 
MAF 
1 rs2230908 CA 2 134 448 769 MGAT5 0.0% n/a n/a 
2 rs34944508 CT 2 134 450 393 MGAT5 97.2% 0.818 0.053 
3 rs79594066 TC 2 134 452 524 MGAT5 98.0% 0.987 0.046 
4 rs35166820 CT 3 186 928 351 ST6GAL1 95.9% 1.000 0.112 
5 rs9814673 CT 3 186 929 863 ST6GAL1 83.5% 0.003 0.329 
6 rs28366038 GA 3 186 929 991 ST6GAL1 92.6% 0.872 0.062 
7 rs1468906 AG 3 186 930 328 ST6GAL1 47.4% 1.000 0.099 
8 rs1042642 AG 3 187 075 641 ST6GAL1 97.4% 0.499 0.472 
9 rs2239611 GA 3 187 075 914 ST6GAL1 96.3% 1.000 0.014 
10 rs2284750 CT 3 187 076 303 ST6GAL1 93.5% 1.000 0.038 
11 rs1801380 GA 3 187 077 852 ST6GAL1 88.5% 0.555 0.138 
12 rs7559 TC 3 187 078 265 ST6GAL1 94.2% 1.000 0.145 
13 rs1042757 GC 3 187 078 342 ST6GAL1 99.2% 0.429 0.474 
14 rs4736674 AT 8 133 456 465 ST3GAL1 98.8% 1.000 0.186 
15 rs4736675 GA 8 133 456 621 ST3GAL1 99.3% 1.000 0.186 
16 rs16904924 TA 8 133 457 034 ST3GAL1 98.7% 1.000 0.186 
17 rs11782689 TC 8 133 457 293 ST3GAL1 99.3% 0.852 0.178 
18 rs2142306 TC 8 133 458 388 ST3GAL1 98.4% 1.000 0.448 
19 rs2922467 GC 8 133 572 946 ST3GAL1 97.2% 0.835 0.256 
20 rs2922471 CT 8 133 574 220 ST3GAL1 96.7% 1.000 0.449 
21 rs3894326 AT 19 5 843 773 FUT3 98.5% 0.712 0.093 
22 rs778986 GA 19 5 844 526 FUT3 98.4% 0.718 0.199 
23 rs812936 AG 19 5 844 638 FUT3 98.9% 1.000 0.208 
24 rs11673407 AG 19 5 851 325 FUT3 96.6% 1.000 0.381 
25 rs2306969 GA 19 5 851 790 FUT3 97.5% 0.624 0.267 
26 rs418821 CG 19 48 696 547 FUT2 98.4% 1.000 0.102 
27 rs16982241 GA 19 48 699 602 FUT2 89.8% 0.313 0.119 
28 rs28362834 CG 19 48 702 748 FUT2 97.5% 0.351 0.100 
29 rs679574 CG 19 48 702 851 FUT2 99.2% 0.400 0.421 
30 rs601338 GA 19 48 703 417 FUT2 99.1% 0.019 0.450 
31 rs602662 GA 19 48 703 728 FUT2 98.5% 0.518 0.437 
32 rs632111 AG 19 48 705 721 FUT2 98.6% 0.757 0.433 
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Table 3. Comparison of the two techniques used for SNP genotype determination  
 TaqMan® OpenArray® Capillary gel electrophoresis 
throughput medium low 
number of steps 1 3 
format stipulated flexible 
pre-designed assays yes no 
number of samples 960 flexible 
number of loci 12, 24, 60, 120, 180, 240 flexible 
required DNA amount ~ 4 ng DNA / locus  < 1 ng DNA / locus 
analysis of repeat variants no yes 
possibility of repeating failed 
analyses 
limited yes 
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Table 4. Association analysis by case–control approach. Minor allele frequency values in 
the 4 subject groups, nominal p values of each individual 2-test as well as the statistical p 
value after correction for multiple testing by Benjamini–Hochberg procedure (false discovery 
rate, FDR) are shown. 
SNP 
Minor allele frequency (MAF) nominal FDR 
control tumor COPD comorbid p p 
rs632111 0.463 0.442 0.403 0.417 0.2284 0.4283 
rs418821 0.110 0.101 0.106 0.076 0.5179 0.6474 
rs601338 0.477 0.459 0.426 0.429 0.3312 0.4969 
rs602662 0.467 0.450 0.403 0.416 0.1552 0.4233 
rs3894326 0.091 0.082 0.115 0.075 0.1969 0.4220 
rs778986 0.180 0.200 0.209 0.214 0.5901 0.7082 
rs28362834 0.094 0.087 0.110 0.120 0.4336 0.5913 
rs812936 0.190 0.202 0.221 0.227 0.5103 0.6656 
rs11673407 0.396 0.390 0.365 0.367 0.6930 0.7700 
rs2306969 0.260 0.239 0.310 0.254 0.0587 0.5866 
rs34944508 0.087 0.033 0.045 0.041 0.0007 0.0207 
rs79594066 0.053 0.060 0.032 0.041 0.1469 0.4407 
rs2922471 0.438 0.441 0.457 0.475 0.7592 0.8135 
rs4736675 0.170 0.203 0.173 0.213 0.2946 0.4910 
rs35166820 0.122 0.087 0.103 0.168 0.0085 0.1268 
rs11782689 0.165 0.193 0.164 0.207 0.3300 0.5211 
rs16904924 0.171 0.202 0.173 0.211 0.3503 0.5005 
rs2142306 0.429 0.485 0.429 0.450 0.2168 0.4337 
rs4736674 0.170 0.205 0.172 0.211 0.2918 0.5150 
rs679574 0.458 0.427 0.393 0.392 0.1316 0.4386 
rs1042757 0.466 0.448 0.478 0.455 0.0854 0.6404 
rs1042642 0.465 0.447 0.472 0.458 0.1071 0.4017 
rs2922467 0.261 0.248 0.270 0.232 0.6851 0.7905 
rs1801380 0.120 0.121 0.151 0.179 0.0887 0.5322 
rs2239611 0.015 0.018 0.011 0.017 0.8091 0.8370 
rs16982241 0.127 0.132 0.093 0.135 0.1789 0.4129 
rs2284750 0.023 0.043 0.048 0.033 0.1723 0.4308 
rs7559 0.124 0.132 0.158 0.186 0.0921 0.4603 
rs28366038 0.056 0.069 0.062 0.063 0.8817 0.8817 
rs9814673 0.360 0.291 0.318 0.367 0.1040 0.4458 
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FIGURES 
Figure 1. SNP genotyping by TaqMan™ probes and by capillary gel electrophoresis. 
Analysis of the rs4736675 SNP is shown. A: The two allele-specific probes are labeled with 
different fluorophores (FAM and VIC) in case of the real-time PCR based method. Thus, 
samples are separated into 3 clusters based on the ratio of the two fluorescent signals 
according to their genotype. B: The primer extension method employs a primer annealing to 
the nucleotide nearby the locus of interest. This is elongated by a fluorescently labeled, chain 
terminator acyclo nucleotide. The obtained products were separated and detected by capillary 
gel electrophoresis. 
 
Figure 2. Allele-wise association analysis of the rs34944508 SNP. The diagram shows the 
allele-frequency values of the SNP in the four subject groups. It is notable that there is >2× 
difference between the minor allele frequencies of controls and lung cancer subjects. 
